🔎 Trials Near Me

Hem › Akut myeloid leukemi › Vermont

Kliniska studier för Akut myeloid leukemi i Vermont

7 studier för Akut myeloid leukemi söker deltagare vid platser i Vermont.

Städer i Vermont

Officiell studietext (engelska)

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
RekryterarFas 2
Ålder 18 till 59 · Alla kön · Uppdaterad 28 sep. 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
RekryterarFas 2
Ålder 18 till 59 · Alla kön · Uppdaterad 22 sep. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • University of Vermont and State Agricultural College, Burlington
RekryterarFas 3
6 Months – 21 Years · Alla kön · Uppdaterad 17 sep. 2026 · NCT04293562

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Vermont Medical Center, Burlington
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 20 aug. 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • University of Vermont, Burlington
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 20 aug. 2026 · NCT06001788

Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.